All In Biotech

Drug Trial Radar · NCT01276223

Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients

A Multi-Center, Randomized, Double-Masked Evaluation of Anti-Inflammatory Treatment in Patients With Dry Eye

Last checked: Nov 20, 2026Latest source record: Mar 11, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 722 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

722

Actual

Start

Feb 2011

Primary completion

Jan 2012

Study completion Jan 2012

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Jan 13, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine if difluprednate ophthalmic emulsion is effective in reducing the ocular symptoms of dry eye disease, as measured by a global Visual Analog Scale (VAS) discomfort score.

Conditions

  • Dry Eye Disease

Interventions

  • Difluprednate 0.05% ophthalmic emulsionDrug

    Topical ocular steroid

  • Difluprednate vehicleOther

    Inactive ingredients used as Run-In and placebo comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline (Week 0) in Visual Analog Scale (VAS) Global Ocular Discomfort Score Over 4 WeeksTime frame: Baseline, up to 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Contact Alcon Call Center at 1-888-451-3937 for Trial Locations

    Fort Worth, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.